난소암 | 바이오모아

CGTBiologicstaleHe HuangPhase 2

GC022F CAR-T cells (GC022F CAR-T cells)

Relapsed and Refractory; Lymphoid Hematological Malignancies · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleSinobioway Cell Therapy Co., Lt…Preclinical

GD2-targeted CAR-T cells (GD2-targeted CAR-T cells)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+3

CGTBiologicstaleNationwide Children's HospitalPhase 2

GEM/DOX + TGFBi expanded NK cells (GEM/DOX + TGFBi expanded NK cells)

Pediatric Sarcoma, Refractory; Pediatric Sarcoma, Relapsed · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

CGTBiologicstaleStanford UniversityPhase 1

GPC2-CAR T cells (GPC2-CAR T cells)

Medulloblastoma; Central Nervous System Embryonal Tumor · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

CGTBiologicstaleEssen BiotechPhase 2

GPC3 CD146 CAR-T cells (GPC3 CD146 CAR-T cells)

Ovarian Cancer; Ovarian Carcinoma · Ovarian Cancer

#OvarianCancer#CGT#Phase2#세포유전치료#CAR-T+3

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab as Consolidation therapy (Glofitamab as Consolidation therapy)

Relapsed /Refractory DLBCL · FRα

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

ADCBiologicstaleNovartis PharmaceuticalsPhase 1

HKT288 (HKT288)

Epithelial Ovarian Cancer; Renal Cell Carcinoma · Epithelial Ovarian Cancer

#EpithelialOvarianCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 DISCONTINUED

ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-007 (HWK-007)

Endometrial Cancer; Ovarian Cancer · EGFR

#EGFR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

ADCBiologicstaleWhitehawk Therapeutics, Inc.Phase 1

HWK-016, MUCIN-16-targeted ADC (HWK-016, MUCIN-16-targeted ADC)

PROC; Platinum Resistant Ovarian Cancer · PROC

#PROC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

CGTBiologicstaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 90%임상시험 1상태 DISCONTINUED

CGTBiologicstaleThe First Hospital of Jilin Uni…Phase 2

IL-15-armored CAR-T cells (IL-15-armored CAR-T cells)

Relapsed/Refractory Multiple Myeloma; Plasma Cell Leukemia (PCL) · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

효능 ORR 50%임상시험 1상태 RECRUITING

AntibodystaleChinese Academy of Medical Scie…Phase 2

Ibrutinib Combined With Rituximab (Ibrutinib Combined With Rituximab)

DLBCL; MYD88 Gene Mutation · FRα

CGTBiologicstaleTcelltech Inc.Phase 1

In Vivo CAR-T Therapy (In Vivo CAR-T Therapy)

Relapsed or Refractory Hematologic Malignancies · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleJanssenPhase 2

Infliximab and Basiliximab (Infliximab and Basiliximab)

Graft Versus Host Disease; Steroid Refractory GVHD · FRα

CGTBiologicstaleDonghua ZhangPreclinical

효능 ORR 10%임상시험 1상태 DISCONTINUED

Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies (Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies)

Relapsed/Refractory B-cell Malignancies · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+4

AntibodystaleHospices Civils de LyonPhase 2

nivolumab (Opdivo, IP, Intraperitoneal, Intraperitoneal (IP) nivolumab infusion)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2

AntibodystaleSanofiPhase 2

Isatuximab SC-OBDS (Isatuximab SC-OBDS)

Plasma Cell Myeloma Refractory · FRα

#FR#Antibody#Phase2#항체#면역항체+3

CGTBiologicstaleCancer Institute and Hospital, …Phase 1

KSX01-TCRT cell therapy (KSX01-TCRT cell therapy)

Refractory Solid Tumors; Relapsed Solid Tumors · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4